Kasper Madsen

423 total citations
32 papers, 255 citations indexed

About

Kasper Madsen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Kasper Madsen has authored 32 papers receiving a total of 255 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Kasper Madsen's work include Cancer Immunotherapy and Biomarkers (14 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Diabetes Treatment and Management (5 papers). Kasper Madsen is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Pancreatic and Hepatic Oncology Research (11 papers) and Diabetes Treatment and Management (5 papers). Kasper Madsen collaborates with scholars based in Denmark, Germany and United States. Kasper Madsen's co-authors include Bianca Hemmingsen, Bernd Richter, Maria-Intí Metzendorf, Julia S. Johansen, Dorte Nielsen, Inge Marie Svane, Inna M. Chen, Susann Theile, Torben Lorentzen and Jane Preuss Hasselby and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Cochrane Database of Systematic Reviews.

In The Last Decade

Kasper Madsen

27 papers receiving 254 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kasper Madsen Denmark	8	123	68	64	39	36	32	255
Cristina Boschini Italy	7	70 0.6×	38 0.6×	58 0.9×	38 1.0×	25 0.7×	16	208
Bo Ma China	6	78 0.6×	95 1.4×	37 0.6×	40 1.0×	66 1.8×	16	326
N. Varol United Kingdom	7	89 0.7×	57 0.8×	137 2.1×	13 0.3×	37 1.0×	26	294
Annie Lukanova Sweden	6	82 0.7×	66 1.0×	49 0.8×	19 0.5×	15 0.4×	6	220
Chien‐Ho Lee Taiwan	10	80 0.7×	57 0.8×	24 0.4×	19 0.5×	69 1.9×	19	269
Alina Sokup Poland	9	42 0.3×	81 1.2×	35 0.5×	22 0.6×	33 0.9×	20	263
Shirley Mo United States	6	82 0.7×	35 0.5×	18 0.3×	45 1.2×	42 1.2×	11	178
Usha Sriram India	8	170 1.4×	150 2.2×	107 1.7×	9 0.2×	55 1.5×	13	435
Henrik Csaba Horváth Hungary	10	52 0.4×	74 1.1×	62 1.0×	18 0.5×	42 1.2×	20	316
Mirella Fortunato Italy	7	73 0.6×	34 0.5×	60 0.9×	19 0.5×	23 0.6×	13	281

Countries citing papers authored by Kasper Madsen

Since Specialization

Citations

This map shows the geographic impact of Kasper Madsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kasper Madsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kasper Madsen more than expected).

Fields of papers citing papers by Kasper Madsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kasper Madsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kasper Madsen. The network helps show where Kasper Madsen may publish in the future.

Co-authorship network of co-authors of Kasper Madsen

This figure shows the co-authorship network connecting the top 25 collaborators of Kasper Madsen. A scholar is included among the top collaborators of Kasper Madsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kasper Madsen. Kasper Madsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2025). Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. Journal of Clinical Oncology. 43(18). 2107–2118. 8 indexed citations

Borch, Troels Holz, Rikke Andersen, Helle Westergren Hendel, et al.. (2025). Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes. Journal for ImmunoTherapy of Cancer. 13(2). e010575–e010575. 1 indexed citations

Donia, Marco, Kasper Madsen, Henrik Schmidt, et al.. (2025). Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab. British Journal of Cancer. 133(3). 337–345. 1 indexed citations

Palshof, Jesper Andreas, Niels Fristrup, Niels Viggo Jensen, et al.. (2025). Nationwide Real-World Outcomes of Trial Eligible and Trial Ineligible Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab. Clinical Genitourinary Cancer. 23(6). 102450–102450.

Donia, Marco, Kasper Madsen, Henrik Schmidt, et al.. (2025). Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma. European Journal of Cancer. 221. 115402–115402.

Johansen, Julia S., Finn Ole Larsen, Susann Theile, et al.. (2024). Nivolumab with or without Ipilimumab Combined with Stereotactic Body Radiotherapy in Patients with Metastatic Biliary Tract Cancer: A Randomized Phase 2 Study. Clinical Cancer Research. 30(16). 3428–3437. 3 indexed citations

Bojesen, Stig E., Julia S. Johansen, Bent Ejlertsen, et al.. (2024). Prognostic Value of Pretreatment Plasma C-Reactive Protein in Patients with Early-Stage Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 33(5). 662–670. 1 indexed citations

Møller, Pia Krause, Mirjana Josipović, Uffe Bernchou, et al.. (2024). MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters. Radiotherapy and Oncology. 192. 110090–110090. 2 indexed citations

Madsen, Kasper, et al.. (2024). Dizziness and impaired walking balance in aging patients during chemotherapy. Journal of Geriatric Oncology. 15(8). 102059–102059. 4 indexed citations

10.

Holmstroem, Rikke B., Kasper Madsen, Marco Donia, et al.. (2024). Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma. European Journal of Cancer. 202. 114023–114023. 4 indexed citations

11.

Holmstroem, Rikke B., Kasper Madsen, Marco Donia, et al.. (2024). Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 – Seasonal variation and association with outcome. European Journal of Cancer. 212. 115053–115053. 4 indexed citations

12.

Mikkelsen, Marta Kramer, Andrea Lange, Kasper Madsen, et al.. (2024). Why do older patients with advanced cancer decline participation in an exercise-based trial during oncological treatment? – A mixed methods study. Physiotherapy Theory and Practice. 41(6). 1274–1286.

13.

Madsen, Kasper, Astrid Z. Johansen, Inna M. Chen, et al.. (2023). Combining sCD163 with CA 19-9 Increases the Predictiveness of Pancreatic Ductal Adenocarcinoma. Cancers. 15(3). 897–897. 4 indexed citations

14.

Madsen, Kasper, Ole Larsen, Lars Henrik Jensen, et al.. (2023). Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer. Cancers. 15(4). 1062–1062. 6 indexed citations

15.

Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2023). Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).. Journal of Clinical Oncology. 41(16_suppl). 4147–4147. 5 indexed citations

16.

Chen, Inna M., Julia S. Johansen, Susann Theile, et al.. (2022). Randomized Phase II Study of Nivolumab With or Without Ipilimumab Combined With Stereotactic Body Radiotherapy for Refractory Metastatic Pancreatic Cancer (CheckPAC). Journal of Clinical Oncology. 40(27). 3180–3189. 68 indexed citations

17.

Madsen, Kasper, et al.. (2022). Determination of temporal reproducibility and variability of cancer biomarkers in serum and EDTA plasma samples using a proximity extension assay. Clinical Proteomics. 19(1). 39–39. 4 indexed citations

18.

Chen, Inna M., Marco Donia, Christopher A. Chamberlain, et al.. (2022). Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R). European Journal of Cancer. 180. 125–133. 23 indexed citations

19.

Jensen, Christina, Ole Larsen, Carsten Palnæs Hansen, et al.. (2022). Blood‐based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer. International Journal of Cancer. 152(5). 1036–1049. 7 indexed citations

20.

Madsen, Kasper, et al.. (2020). Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact